

Don S Dizon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/737660/publications.pdf>

Version: 2024-02-01

212
papers

7,130
citations

50276

46
h-index

69250

77
g-index

216
all docs

216
docs citations

216
times ranked

9693
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. <i>Clinical Cancer Research</i> , 2002, 8, 2505-11.	7.0	339
2	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3460-3473.	1.6	318
3	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.	1.6	318
4	Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Gynecologic Oncology</i> , 2016, 143, 3-15.	1.4	208
5	Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1215-1223.	1.6	172
6	Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 1731.	7.1	150
7	Progress and remaining challenges for cancer control in Latin America and the Caribbean. <i>Lancet Oncology</i> , 2015, 16, 1405-1438.	10.7	142
8	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	1.6	141
9	Communicating uncertainty can lead to less decision satisfaction: a necessary cost of involving patients in shared decision making?. <i>Health Expectations</i> , 2011, 14, 84-91.	2.6	140
10	Practical Guidance: The Use of Social Media In Oncology Practice. <i>Journal of Oncology Practice</i> , 2012, 8, e114-e124.	2.5	140
11	Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 92-120.	4.9	136
12	Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 4523-4531.	1.6	122
13	Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5943-5949.	1.6	118
14	Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: Role of caspase and MAPK activation. <i>Gynecologic Oncology</i> , 2006, 103, 261-270.	1.4	115
15	Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P. <i>Journal of Clinical Oncology</i> , 2009, 27, 3104-3108.	1.6	106
16	A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 150, 274-281.	1.4	105
17	Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2015, 33, 786-809.	1.6	102
18	New-generation platinum agents for solid tumors. <i>Future Oncology</i> , 2009, 5, 33-42.	2.4	101

#	ARTICLE	IF	CITATIONS
19	Sexual Health as a Survivorship Issue for Female Cancer Survivors. <i>Oncologist</i> , 2014, 19, 202-210.	3.7	99
20	Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Malignant Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 154-159.	1.6	96
21	Analysis of Patients with Epithelial Ovarian Cancer or Fallopian Tube Carcinoma Retreated with Cisplatin after the Development of a Carboplatin Allergy. <i>Gynecologic Oncology</i> , 2002, 84, 378-382.	1.4	95
22	Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 4693-4700.	1.6	95
23	Importance of clarifying patients' desired role in shared decision making to match their level of engagement with their preferences. <i>BMJ, The</i> , 2013, 347, f7066-f7066.	6.0	94
24	Disease-Specific Hashtags for Online Communication About Cancer Care. <i>JAMA Oncology</i> , 2016, 2, 392.	7.1	91
25	A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2012, 125, 367-371.	1.4	90
26	Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 1238-1247.	1.6	87
27	Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2305-2314.	7.0	85
28	Sex, Intimacy, and the Gynecologic Oncologist. <i>Journal of Psychosocial Oncology</i> , 2007, 25, 61-70.	1.2	82
29	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
30	Ovarian Cancer Associated with Testosterone Supplementation in a Female-to-Male Transsexual Patient. <i>Gynecologic and Obstetric Investigation</i> , 2006, 62, 226-228.	1.6	81
31	Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 2012, 127, 141-146.	1.4	80
32	Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 979-986.	2.5	78
33	Clinicopathologic Analysis of Early-stage Sporadic Ovarian Carcinoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 147-159.	3.7	77
34	Treatment options for advanced endometrial carcinoma. <i>Gynecologic Oncology</i> , 2010, 117, 373-381.	1.4	77
35	Quality of Life after Breast Cancer: Survivorship and Sexuality. <i>Breast Journal</i> , 2009, 15, 500-504.	1.0	76
36	Advances in the Management of Recurrent Endometrial Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 206-212.	1.3	74

#	ARTICLE	IF	CITATIONS
37	Sexual dysfunction in women with cancer. <i>Fertility and Sterility</i> , 2013, 100, 916-921.	1.0	73
38	Sexual Dysfunction in Female Cancer Survivors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 101-106.	1.3	70
39	A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014, 135, 441-445.	1.4	69
40	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 460-474.	4.7	67
41	Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 138, 18-23.	1.4	64
42	Uterine Sarcoma, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1321-1331.	4.9	58
43	A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). <i>Annals of Oncology</i> , 2017, 28, 505-511.	1.2	57
44	Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. <i>Gynecologic Oncology</i> , 2007, 105, 81-83.	1.4	55
45	Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organization's Response for Readiness, Mitigation, and Resilience. <i>JCO Oncology Practice</i> , 2021, 17, 365-374.	2.9	53
46	Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 137, 401-405.	1.4	51
47	Survivorship: Healthy Lifestyles, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1222-1237.	4.9	47
48	Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. <i>Gynecologic Oncology</i> , 2003, 91, 584-590.	1.4	45
49	Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. <i>Gynecologic Oncology</i> , 2003, 91, 123-129.	1.4	43
50	Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 2962-2967.	7.0	41
51	Social media in cancer care: highlights, challenges & opportunities. <i>Future Oncology</i> , 2016, 12, 1549-1552.	2.4	40
52	Breast-Specific Sensuality and Sexual Function in Cancer Survivorship: Does Surgical Modality Matter?. <i>Annals of Surgical Oncology</i> , 2017, 24, 3133-3140.	1.5	40
53	Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. <i>Gynecologic Oncology</i> , 2006, 100, 149-151.	1.4	39
54	Breast cancer and sexual function. <i>Translational Andrology and Urology</i> , 2015, 4, 160-8.	1.4	39

#	ARTICLE	IF	CITATIONS
55	The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. <i>Gynecologic Oncology</i> , 2003, 90, 431-434.	1.4	36
56	Addressing clinical trials: Can the Multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program. <i>Gynecologic Oncology</i> , 2010, 116, 295-300.	1.4	36
57	Medical Therapy of Endometrial Cancer. <i>Drugs</i> , 2012, 72, 705-713.	10.9	36
58	State of the science in cervical cancer: Where we are today and where we need to go. <i>Cancer</i> , 2014, 120, 2282-2288.	4.1	36
59	Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 158, 562-569.	1.4	35
60	Role of ultrasound-guided axillary fine-needle aspiration in the management of invasive breast cancer. <i>American Journal of Surgery</i> , 2006, 192, 458-461.	1.8	34
61	A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, COG-86P.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5500-5500.	1.6	34
62	Intrahepatic arterial infusion of chemotherapy: Clinical results. <i>Seminars in Oncology</i> , 2002, 29, 126-135.	2.2	32
63	Regional Chemotherapy: A Focus on Hepatic Artery Infusion for Colorectal Cancer Liver Metastases. <i>Surgical Oncology Clinics of North America</i> , 2008, 17, 759-771.	1.5	32
64	Cervical cancer control in Latin America: A call to action. <i>Cancer</i> , 2016, 122, 502-514.	4.1	32
65	Sexuality After Cancer: A Model for Male Survivors. <i>Journal of Sexual Medicine</i> , 2016, 13, 70-78.	0.6	32
66	The emerging role of professional social media use in oncology. <i>Future Oncology</i> , 2017, 13, 1281-1285.	2.4	32
67	Survivorship: Nutrition and Weight Management, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1396-1406.	4.9	31
68	PARP inhibitors for targeted treatment in ovarian cancer. <i>Lancet, The</i> , 2017, 390, 1929-1930.	13.7	30
69	Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 313-315.	1.3	30
70	Risks and benefits of Twitter use by hematologists/oncologists in the era of digital medicine. <i>Seminars in Hematology</i> , 2017, 54, 198-204.	3.4	29
71	Pilot study of a multimodal intervention to enhance sexual function in survivors of hematopoietic stem cell transplantation. <i>Cancer</i> , 2018, 124, 2438-2446.	4.1	28
72	Going Flat After Mastectomy: Patient-Reported Outcomes by Online Survey. <i>Annals of Surgical Oncology</i> , 2021, 28, 2493-2505.	1.5	28

#	ARTICLE	IF	CITATIONS
73	Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA) >2m ² . <i>Gynecologic Oncology</i> , 2009, 114, 53-56.	1.4	27
74	Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study. <i>BMJ Open</i> , 2013, 3, e003138.	1.9	27
75	Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53. <i>Obstetrics and Gynecology International</i> , 2013, 2013, 1-10.	1.3	25
76	Management and outcomes for elderly women with vulvar cancer over time. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 719-727.	2.3	25
77	Chemotherapy in ovarian germ cell tumors: A systematic review. <i>Gynecologic Oncology</i> , 2016, 141, 602-607.	1.4	24
78	Communication About Sexuality in Advanced Illness Aligns With a Palliative Care Approach to Patient-Centered Care. <i>Current Oncology Reports</i> , 2016, 18, 11.	4.0	23
79	Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-10.	2.1	23
80	Placental Mesenchymal Dysplasia Presenting as a Twin Gestation With Complete Molar Pregnancy. <i>Obstetrics and Gynecology</i> , 2011, 118, 445-449.	2.4	22
81	Advance care planning as a shared endeavor: completion of ACP documents in a multidisciplinary cancer program. <i>Psycho-Oncology</i> , 2017, 26, 67-73.	2.3	21
82	Physician Perceptions of the Use of Social Media for Recruitment of Patients in Cancer Clinical Trials. <i>JAMA Network Open</i> , 2019, 2, e1911528.	5.9	21
83	Waging War on War Metaphors in Cancer and COVID-19. <i>JCO Oncology Practice</i> , 2020, 16, 624-627.	2.9	21
84	Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2. <i>Seminars in Radiation Oncology</i> , 2016, 26, 3-8.	2.2	20
85	Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 204-210.	1.3	20
86	Survivorship care planning in gynecologic oncology—perspectives from patients, caregivers, and health care providers. <i>Journal of Cancer Survivorship</i> , 2018, 12, 762-774.	2.9	19
87	ADX51001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage I of the phase II GOG/NRG0265 study. <i>Journal of Clinical Oncology</i> , 2016, 34, 5516-5516.	1.6	19
88	eSyM: An Electronic Health Record–Integrated Patient-Reported Outcomes–Based Cancer Symptom Management Program Used by Six Diverse Health Systems. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100137.	2.1	19
89	Chemotherapy-induced dyspareunia: a case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma. <i>Gynecologic Oncology</i> , 2004, 93, 561-563.	1.4	18
90	Clinical Characteristics and Choices Regarding Risk-Reducing Surgery in BRCA Mutation Carriers. <i>Gynecologic and Obstetric Investigation</i> , 2010, 69, 270-273.	1.6	18

#	ARTICLE	IF	CITATIONS
91	Patterns of Recurrence in Patients Treated With Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1219-1225.	2.5	18
92	Cervical Cancer Prevention: Asian-American Women's Knowledge and Participation in Screening Practices. <i>Women's Health Issues</i> , 2014, 24, e231-e236.	2.0	18
93	Prostate Cancer Social Media: In YouTube We Trust?. <i>European Urology</i> , 2019, 75, 568-569.	1.9	18
94	A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 236-242.	1.4	17
95	A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014, 135, 44-48.	1.4	16
96	Survivorship: Immunizations and Prevention of Infections, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1098-1111.	4.9	16
97	Oral Thalidomide as Palliative Chemotherapy in Women with Advanced Ovarian Cancer. <i>Journal of Palliative Medicine</i> , 2007, 10, 61-66.	1.1	15
98	Defining social support systems for women with breast cancer. <i>American Journal of Surgery</i> , 2007, 194, 501-503.	1.8	15
99	A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2007, 25, 335-341.	2.6	15
100	Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2011, 123, 182-186.	1.4	15
101	The Needs of Women Treated for Ovarian Cancer: Results From a #gynscm Twitter Chat. <i>Journal of Patient-centered Research and Reviews</i> , 2018, 5, 149-157.	0.9	15
102	Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. <i>Gynecologic Oncology</i> , 2006, 103, 72-74.	1.4	14
103	Antimitotic Inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 607-628.	2.2	14
104	Clear cell cancer of the ovary. <i>Current Opinion in Oncology</i> , 2013, 25, 553-557.	2.4	14
105	Preparing for Survivorship: Quality of Life in Breast Cancer Survivors. <i>Journal of Sexual Medicine</i> , 2013, 10, 16-20.	0.6	14
106	Survivorship: Screening for Cancer and Treatment Effects, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1526-1531.	4.9	14
107	Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 177-178.	3.8	14
108	A social media survey of women who do not pursue reconstruction after mastectomy for breast cancer: Characterizing the "Going Flat" movement. <i>Breast Journal</i> , 2020, 26, 1455-1457.	1.0	14

#	ARTICLE	IF	CITATIONS
109	Two for good measure: Six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 100, 417-421.	1.4	13
110	HER-dimerization inhibitors: evaluating pertuzumab in women's cancers. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 243-250.	3.1	13
111	Precision medicine and personalized breast cancer: combination pertuzumab therapy. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 95.	0.7	13
112	Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv442.	6.3	13
113	Twitter 101 and beyond: introduction to social media platforms available to practicing hematologist/oncologists. <i>Seminars in Hematology</i> , 2017, 54, 177-183.	3.4	13
114	Cluster Analysis Demonstrates the Need to Individualize Care for Cancer Survivors. <i>Oncologist</i> , 2018, 23, 1474-1481.	3.7	13
115	Does One Person Provide It All? Primary Support and Advanced Care Planning for Women With Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1412-1416.	1.6	12
116	Sexuality, fertility and pregnancy following breast cancer treatment. <i>Gland Surgery</i> , 2018, 7, 404-410.	1.1	12
117	Dyspnea during Thalidomide Treatment for Advanced Ovarian Cancer. <i>Annals of Pharmacotherapy</i> , 2005, 39, 962-965.	1.9	11
118	For Women Receiving Chemotherapy for Clinically Apparent Early Ovarian Cancer, Is There a Benefit to Surgical Staging?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 39-42.	1.3	11
119	People with cancer are likely to accept the COVID-19 vaccine, but politics tracks with attitudes: An inspire and COSMO survey.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1531-1531.	1.6	11
120	A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2018, 151, 202-207.	1.4	10
121	Investigator Use of Social Media for Recruitment of Patients for Cancer Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2031202.	5.9	10
122	Now, More Than Ever, Is the Time for Early and Frequent Advance Care Planning. <i>Journal of Clinical Oncology</i> , 2020, 38, 2956-2959.	1.6	9
123	Advances in the diagnosis and treatment of uterine sarcomas. <i>Discovery Medicine</i> , 2014, 17, 339-45.	0.5	9
124	Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial. <i>Trials</i> , 2022, 23, .	1.6	9
125	The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. <i>Cancer Discovery</i> , 2022, 12, 1620-1624.	9.4	9
126	Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline <i>BRCA1</i> Mutation. <i>Oncologist</i> , 2018, 23, 650-653.	3.7	8

#	ARTICLE	IF	CITATIONS
127	Sexual Health Issues in Cancer Survivors. <i>Seminars in Oncology Nursing</i> , 2020, 36, 150981.	1.5	8
128	Sexual Ramifications of Medical Illness. <i>Clinical Obstetrics and Gynecology</i> , 2009, 52, 691-701.	1.1	7
129	Locally Advanced Vulvar Cancer in Elderly Women. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 279-282.	1.3	7
130	The Power of Words: Discussing Decision Making and Prognosis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 442-446.	3.8	7
131	A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 144, 101-106.	1.4	7
132	Incorporating Digital Tools to Improve Clinical Trial Infrastructure: A White Paper From the Digital Engagement Committee of SWOG. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-8.	2.1	7
133	Distress: Characterizing What Causes the Thermometer to Shift in Patients with Newly Diagnosed Breast Cancer Attending a Multidisciplinary Clinic. <i>Annals of Surgical Oncology</i> , 2019, 26, 3204-3209.	1.5	7
134	Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. <i>Gynecologic Oncology</i> , 2019, 153, 223-229.	1.4	7
135	Identification of Transgender People With Cancer in Electronic Health Records: Recommendations Based on CancerLinQ Observations. <i>JCO Oncology Practice</i> , 2021, 17, e336-e342.	2.9	7
136	A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. <i>Gynecologic Oncology</i> , 2016, 141, 108-112.	1.4	6
137	Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection. <i>Gynecologic Oncology</i> , 2017, 144, 241-242.	1.4	6
138	Palliative Total Pelvic Exenteration for Gynecologic Cancers: A Cross-sectional Study of Society of Gynecologic Oncology Members. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1796-1804.	2.5	6
139	New Cardiac Abnormalities After Radiotherapy in Breast Cancer Patients Treated With Trastuzumab. <i>Clinical Breast Cancer</i> , 2020, 20, 246-252.	2.4	6
140	Disease-specific hashtags for online communication about cancer care.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6520-6520.	1.6	6
141	Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and <i>POLE</i> -mutated recurrent or persistent endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5615-TPS5615.	1.6	6
142	Clinical characteristics of women presenting with skin-only recurrence of breast cancer. <i>American Journal of Surgery</i> , 2007, 194, 494-496.	1.8	5
143	Breast Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 150-156.	1.1	5
144	Clinical Trials in the Era of Digital Engagement: A SWOG Call to Action. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 254-258.	2.1	5

#	ARTICLE	IF	CITATIONS
145	Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 667-676.	2.5	5
146	A phase 2 study of live-attenuated listeria monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5617-TPS5617.	1.6	5
147	Is There a Taxane-Free Interval That Predicts Response to Taxanes as a Later-Line Treatment of Recurrent Ovarian or Primary Peritoneal Cancer?. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 343-347.	2.5	4
148	Advance Care Planning Decisions of Women with Cancer: Provider Recognition and Stability of Choices. <i>Journal of Psychosocial Oncology</i> , 2009, 27, 383-395.	1.2	4
149	The effects of age on treatment and outcomes in women with stages IB1â€“IIB cervical cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 374-381.	1.0	4
150	Is Tumor Board Relevant?. <i>Breast Journal</i> , 2013, 19, 351-353.	1.0	4
151	Survivorship in Gynecologic Cancer: Enduring the Treatment toward a New Normal. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e288-e294.	3.8	4
152	Improving quality of life in female cancer survivors: current status and future questions. <i>Future Oncology</i> , 2014, 10, 1015-1026.	2.4	4
153	Axillary Ultrasound Fine Needle Aspiration Biopsy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 702-707.	1.3	4
154	Social Media and Oncology: The Time Is Now. <i>JCO Oncology Practice</i> , 2022, 18, 525-527.	2.9	4
155	Analysis of Hematology and Oncology Fellowship Website Content and Diversity Representation. <i>JCO Oncology Practice</i> , 2022, , OP2100623.	2.9	4
156	Novel Antiangiogenic Therapies in Ovarian Cancer. <i>Women's Health</i> , 2012, 8, 447-453.	1.5	3
157	Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. <i>Practical Radiation Oncology</i> , 2018, 8, 206-212.	2.1	3
158	Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. <i>Cancers</i> , 2021, 13, 3196.	3.7	3
159	Netiquette for social media engagement for oncology professionals. <i>Future Oncology</i> , 2022, 18, 1133-1141.	2.4	3
160	The Differential Diagnosis of Dyspnea in a Woman with Metastatic Breast Cancer-Consideration Beyond Pulmonary Embolism. <i>Breast Journal</i> , 2008, 14, 90-91.	1.0	2
161	Society of Gynecologic Oncologists Position Paper: Breast Cancer Care. <i>Gynecologic Oncology</i> , 2008, 110, 7-12.	1.4	2
162	Pushing the bar in treatment of cervical cancer: What can comprehensive cancer centers do on their own?. <i>Gynecologic Oncology</i> , 2013, 131, 464-466.	1.4	2

#	ARTICLE	IF	CITATIONS
163	Where do Antiangiogenic Agents Belong in the Treatment Algorithm for Ovarian Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 519-525.	1.3	2
164	Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy. Clinical Obstetrics and Gynecology, 2016, 59, 756-771.	1.1	2
165	What's the Harm?. Oncologist, 2017, 22, 1006-1007.	3.7	2
166	Desire to address costs at time of treatment decisions among patients with metastatic breast cancer.. Journal of Clinical Oncology, 2019, 37, 6640-6640.	1.6	2
167	Survivorship care planning in gynecologic oncology: Perspectives from patients, caregivers, and health care providers.. Journal of Clinical Oncology, 2018, 36, 63-63.	1.6	2
168	Ethics-Centered Guidelines for Social Media Use by Oncology Professionals: A Call to Action. JCO Oncology Practice, 2022, 18, 537-540.	2.9	2
169	Using Social Media for Clinical Research: Recommendations and Examples From the Brown-Lifespan Center for Digital Health. Journal of Medical Internet Research, 2022, 24, e35804.	4.3	2
170	HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology. Expert Opinion on Drug Discovery, 2008, 3, 1363-1369.	5.0	1
171	New advances in the treatment of endometrial cancer. Clinical Investigation, 2011, 1, 413-422.	0.0	1
172	Outcomes for Women Receiving Bevacizumab for Treatment of Ovarian Cancer Versus Other Solid Tumors at an Academic Oncology Center. Clinical Ovarian and Other Gynecologic Cancer, 2013, 6, 21-24.	0.1	1
173	Guilt and the Burden on Oncology Providers. Oncologist, 2014, 19, 441-442.	3.7	1
174	Development of a Breast Cancer Advocacy and Access Health Program in Nicaragua. Breast Journal, 2015, 21, 570-571.	1.0	1
175	Sexual Recovery After Cancer. Current Sexual Health Reports, 2015, 7, 63-69.	0.8	1
176	Toward Eubiosia: Bridging Oncology and Palliative Care. Oncologist, 2015, 20, 5-6.	3.7	1
177	Reply to the letter to the editor "Integrating communication as a core skill in the global curriculum for medical oncology" by Horlait et al.. Annals of Oncology, 2017, 28, 905-906.	1.2	1
178	Protecting Patient Privacy in Narratives: The Lifespan-Brown Checklist for Appropriate Use of Patient Narratives. Oncologist, 2019, 24, 285-287.	3.7	1
179	Genomic landscape of angiosarcoma: A targeted and immunotherapy biomarker analysis of 143 patients.. Journal of Clinical Oncology, 2020, 38, 11545-11545.	1.6	1
180	Long-term follow up for a phase I trial HER2/neu-targeted T cells in women with advanced breast cancer.. Journal of Clinical Oncology, 2014, 32, 3075-3075.	1.6	1

#	ARTICLE	IF	CITATIONS
181	Social Media and the Quest for Equity and Diversity in Oncology: On Safe Spaces and the Concept of the Public Physician. JCO Oncology Practice, 2022, 18, 572-577.	2.9	1
182	Incorporating Targeted Treatments into Standard Regimens: Whither the Role of Established Doses?. Cancer Investigation, 2004, 22, 954-954.	1.3	0
183	Patterns of Cellular Distribution with the Sentinel Node Positive for Breast Cancer. International Journal of Breast Cancer, 2011, 2011, 1-4.	1.2	0
184	Feels good, looks better: Proportion of women completing all stages of breast reconstruction after mastectomy for breast cancer treatment or prophylaxis. Gynecologic Oncology, 2012, 125, S47-S48.	1.4	0
185	Why DOMA is unconstitutional, beyond the traditional views of same sex relationships. Journal of Assisted Reproduction and Genetics, 2013, 30, 861-861.	2.5	0
186	Narratives in Oncology. Oncologist, 2014, 19, 789-789.	3.7	0
187	My Father's Final Lesson. Oncologist, 2014, 19, 1110-1111.	3.7	0
188	Delay in chemotherapy administration adversely affects overall survival in elderly ovarian cancer patients. Gynecologic Oncology, 2015, 136, 403.	1.4	0
189	Breast Cancer Risk Assessment. Obstetrical and Gynecological Survey, 2016, 71, 156-157.	0.4	0
190	A Multimodal Intervention Enhances Sexual Function and Quality of Life (QOL) in Hematopoietic Stem Cell Transplant (HCT) Survivors. Biology of Blood and Marrow Transplantation, 2018, 24, S252.	2.0	0
191	Abstract PS7-57: Patient risk factors for loss to breast oncologic follow up. , 2021, , .		0
192	Sporadic uterine Lymphangiomyomatosis (LAM): Report of a unique case arising in the lower uterine segment with short review. Gynecologic Oncology Reports, 2021, 37, 100812.	0.6	0
193	Evaluation of the Female with Sexual Dysfunction. , 2011, , 351-356.		0
194	The effects of age on treatment and outcomes in women with stage IB-IIb cervical cancer.. Journal of Clinical Oncology, 2012, 30, 5100-5100.	1.6	0
195	Effect of female-dominant support networks on end-of-life decision making among women with advanced or recurrent cancer.. Journal of Clinical Oncology, 2013, 31, 6590-6590.	1.6	0
196	Achieving quality: Comparing recommendations for cancer care between NCCN and ESMO.. Journal of Clinical Oncology, 2013, 31, 6579-6579.	1.6	0
197	The role of oncologic health care providers in end of life discussions for women with recurrent gynecologic or breast cancer.. Journal of Clinical Oncology, 2013, 31, e20543-e20543.	1.6	0
198	Results of a phase I pharmacokinetic study of intraperitoneal bortezomib (B) and carboplatin (C) in patients with persistent or recurrent ovarian cancer (OC): An NRG/Gynecologic Oncology Group study.. Journal of Clinical Oncology, 2015, 33, 5515-5515.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Global Cancer Institute (GCI) multi-disciplinary tumor boards (MTBs) as an educational tool to improve guideline-based cancer clinical practice in low- and middle-income countries (LMICs).. Journal of Clinical Oncology, 2016, 34, e18007-e18007.	1.6	0
200	A description of a small cohort of Argentinian women presenting with cervical cancer (CC) highlighting the need for CC control in Latin America (LA).. Journal of Clinical Oncology, 2016, 34, e17026-e17026.	1.6	0
201	A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus: An NRG/Gynecologic Oncology Group study.. Journal of Clinical Oncology, 2016, 34, 5585-5585.	1.6	0
202	A multimodal intervention to enhance sexual function and quality of life (QOL) in hematopoietic stem cell transplant (HCT) survivors.. Journal of Clinical Oncology, 2017, 35, 10013-10013.	1.6	0
203	A multimodal intervention to enhance sexual function and quality of life (QOL) in hematopoietic stem cell transplant (HCT) survivors.. Journal of Clinical Oncology, 2017, 35, 191-191.	1.6	0
204	Cluster analysis to demonstrate the need to individualize care for cancer survivors.. Journal of Clinical Oncology, 2018, 36, 62-62.	1.6	0
205	Considering cost and value with patients in clinic.. Journal of Clinical Oncology, 2018, 36, e18905-e18905.	1.6	0
206	Identifying sexual orientation in the medical record: A first step towards understanding gynecologic cancer disparities.. Journal of Clinical Oncology, 2018, 36, e18641-e18641.	1.6	0
207	The individualized Goals of Care Discussion Guide: A simple tool to empower patients with metastatic breast cancer.. Journal of Clinical Oncology, 2019, 37, 11622-11622.	1.6	0
208	After cancer, whatâ€™s more important? The survivorship care plan or the survivorship care visit?. Journal of Clinical Oncology, 2019, 37, 11618-11618.	1.6	0
209	Endometrial Cancer Genetic Classification and Its Clinical Application. , 2020, , 23-47.		0
210	Does age contribute to distress in new geriatric oncology patients?. Journal of Clinical Oncology, 2020, 38, e24023-e24023.	1.6	0
211	Appropriateness of opioid prescribing in cancer patients.. Journal of Clinical Oncology, 2020, 38, e24129-e24129.	1.6	0
212	Identification of transgender people with cancer in electronic health records (EHR): Recommendations based on CancerLinQ observations.. Journal of Clinical Oncology, 2020, 38, e19046-e19046.	1.6	0